A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors

Trial Profile

A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Conatumumab (Primary) ; Ganitumab
  • Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen; NantCell
  • Most Recent Events

    • 01 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top